TMS Co., Ltd. (4891.T)
JPY 220.0
(0.0%)
JPY 220.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 97.68 Million JPY | 28.26% |
| 2022 | 76.16 Million JPY | -73.44% |
| 2021 | 286.78 Million JPY | 231.99% |
| 2020 | 86.38 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 113.21 Million JPY | 15.89% |
| 2024 Q2 | 99.07 Million JPY | -12.49% |
| 2023 Q3 | 69.77 Million JPY | 13.93% |
| 2023 FY | 97.68 Million JPY | 28.26% |
| 2023 Q2 | 61.23 Million JPY | -13.36% |
| 2023 Q1 | 70.68 Million JPY | -7.19% |
| 2023 Q4 | 97.68 Million JPY | 40.02% |
| 2022 Q2 | 92 Million JPY | 0.0% |
| 2022 Q4 | 76.16 Million JPY | -56.73% |
| 2022 Q3 | 176 Million JPY | 91.3% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 96.991% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -54.057% |
| GNI Group Ltd. | 26.34 Billion JPY | 99.629% |
| Linical Co., Ltd. | 10.3 Billion JPY | 99.052% |
| Trans Genic Inc. | 3.81 Billion JPY | 97.438% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 83.448% |
| Soiken Holdings Inc. | 697.02 Million JPY | 85.985% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 96.766% |
| AnGes, Inc. | 2.78 Billion JPY | 96.498% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | 80.98% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.892% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | 72.347% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 94.079% |
| Carna Biosciences, Inc. | 472.35 Million JPY | 79.319% |
| CanBas Co., Ltd. | 91.98 Million JPY | -6.198% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 91.067% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 87.937% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 83.547% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 97.704% |
| PeptiDream Inc. | 29.11 Billion JPY | 99.664% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 82.756% |
| Ribomic Inc. | 155.8 Million JPY | 37.302% |
| SanBio Company Limited | 2.25 Billion JPY | 95.668% |
| Healios K.K. | 11.28 Billion JPY | 99.134% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | 61.122% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 73.526% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | 59.549% |
| StemRIM | 187 Million JPY | 47.76% |
| CellSource Co., Ltd. | 677.73 Million JPY | 85.586% |
| FunPep Company Limited | 189.32 Million JPY | 48.401% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 83.635% |
| Stella Pharma Corporation | 1.44 Billion JPY | 93.233% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -6.771% |
| Cuorips Inc. | 200.96 Million JPY | 51.389% |
| K Pharma,Inc. | 209.13 Million JPY | 53.289% |
| Takara Bio Inc. | 11.42 Billion JPY | 99.145% |
| ReproCELL Incorporated | 741.03 Million JPY | 86.817% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 89.355% |
| StemCell Institute Inc. | 3.85 Billion JPY | 97.463% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 89.246% |
| CellSeed Inc. | 301.04 Million JPY | 67.55% |